Q4 2025 Tenon Medical Inc Earnings Call Transcript
Key Points
- Tenon Medical Inc (TNON) achieved record full year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024.
- The company reported a significant 92% increase in fourth-quarter revenue, reaching $1.5 million, driven by growth in surgical procedures and new physician users.
- Tenon Medical Inc (TNON) received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding their product portfolio.
- The company successfully completed early clinical cases with SImmetry+, validating the system's readiness for broader market adoption.
- Tenon Medical Inc (TNON) strengthened its financial position with a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing flexibility for expansion and product rollouts.
- Operating expenses increased to $3.9 million in Q4 2025, up from $3.5 million in the prior year quarter, primarily due to higher variable expenses in sales and marketing.
- The company reported a net loss of $2.8 million for the fourth quarter of 2025, although this was an improvement from the $3.1 million loss in the same quarter of 2024.
- Cash and cash equivalents decreased to $3.8 million as of December 31, 2025, compared to $6.5 million at the end of 2024.
- Despite revenue growth, Tenon Medical Inc (TNON) continues to operate at a loss, with a net loss of $12.6 million for the full year 2025.
- The company faces ongoing challenges in balancing training and selling efforts for new products, which could impact the pace of adoption and revenue growth.
Greetings, and welcome to the Tenon Medical fourth-quarter and full year 2025 financial results and corporate update conference call. As a reminder, this call is being recorded.
Your hosts today are Steve Foster, President and Chief Executive Officer, and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the fourth quarter and full year ended December 31, 2025, and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website, www.tenonmed.com.
Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates and other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially.
You
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
